Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
University of Maryland, Baltimore
Study ID
NCT00003397
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • filgrastim — BIOLOGICAL
  • rituximab — BIOLOGICAL
  • sargramostim — BIOLOGICAL
  • carmustine — DRUG
  • cisplatin — DRUG
  • cyclophosphamide — DRUG
  • dexamethasone — DRUG
  • etoposide — DRUG
  • gemcitabine hydrochloride — DRUG
  • melphalan — DRUG
  • paclitaxel — DRUG
  • bone marrow ablation with stem cell support — PROCEDURE
  • peripheral blood stem cell transplantation — PROCEDURE

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus combination chemotherapy and rituximab in treating patients with non-Hodgkin's lymphoma.

Key Dates

Start date
Sep 30, 1998
Status verified
Oct 2019
Primary completion
Dec 31, 2002
Completion
Dec 31, 2002

Study Design

Enrollment
25 participants (estimated)
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Marlene & Stewart Greenebaum Cancer Center, University of MarylandBaltimoreMaryland21201-

Find similar trials in Baltimore, MD

By research site
Marlene & Stewart Greenebaum Cancer Center, University of Maryland· Baltimore, MD

Related Studies